Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer
Immunoproteasome subunits, in particular PSMB9, are immune microenvironment-related molecules of MIBC and are promising signatures for survival prediction in response to immunotherapy of MIBC.
Authors
- Michael Basler (ORCID: https://orcid.org/0000-0002-9428-2349)
- Qingyan Jiang (ORCID: https://orcid.org/0000-0003-3466-2443)
- XinJian Wang
- Xinyu Chen
- Hang You
- Nan Liu (ORCID: https://orcid.org/0000-0002-8314-0900)
- Teng Zhang (ORCID: https://orcid.org/0000-0002-0978-2876)
- Yuan Li (ORCID: https://orcid.org/0000-0001-9809-9894)
- Yuan Fang
- Jun Li (ORCID: https://orcid.org/0000-0003-0891-4328)
- Han Chen (ORCID: https://orcid.org/0009-0007-9789-706X)
Institutions
- Chongqing University (CN)
- University of Konstanz (DE)
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Biotechnology Institute Thurgau (CH)
- Chongqing Cancer Hospital (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1186/s12967-025-06207-w
- Citations
- 5
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 10.03
Funders
- Deutsche Forschungsgemeinschaft
- National Natural Science Foundation of China